Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review
Eptinezumab, a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), was recently approved in Europe for the prophylactic treatment of migraine in adults who have at least four migraine days a month. Eptinezumab is administered by intravenous infusion every 12 weeks. During recent...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2024-03-01
|
| Edice: | Frontiers in Neurology |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fneur.2024.1355877/full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|